Dr. McTiernan has reported that he has no relationships relevant to the contents of this paper to disclose. Because this appears to be the first utilization of a gene-therapy vector to achieve BAG3 overexpression in any disease setting, it is a reassuring sign that no deaths were observed in any mice receiving AAV-BAG3. In addition, the improvements of systolic function and calcium handling are encouraging.
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However, several limitations should also be considered. For example, mice were not followed for more 
